CYP2J2 Antibody

說明書

中文名稱：

CYP2J2兔多克隆抗體
貨號：

CSB-PA006430ESR2HU
規格：

￥440
圖片：
Western blot
All lanes: CYP2J2 antibody at 4μg/ml
Lane 1: Mouse skeletal muscle tissue
Lane 2: Rat liver tissue
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 58 kDa
Observed band size: 58 kDa

Immunohistochemistry of paraffin-embedded human breast cancer using CSB-PA006430ESR2HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human liver tissue using CSB-PA006430ESR2HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) CYP2J2 Polyclonal antibody
Uniprot No.：

P51589
基因名：

CYP2J2
別名：

Arachidonic acid epoxygenase antibody; CP2J2_HUMAN antibody; CPJ2 antibody; CYP2J2 antibody; CYPIIJ2 antibody; Cytochrome P450 2J2 antibody; Cytochrome P450 family 2 subfamily J polypeptide 2 antibody; Cytochrome P450 subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2 antibody; Cytochrome P450 subfamily IIJ polypeptide 2 antibody; Flavoprotein linked monooxygenase antibody; Microsomal monooxygenase antibody; OTTHUMP00000010550 antibody
宿主：

Rabbit
反應種屬：

Human, Mouse, Rat
免疫原：

Recombinant Human Cytochrome P450 2J2 protein (328-502AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) in the cardiovascular system. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of PUFA. Converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EpETrE), likely playing a major role in the epoxidation of endogenous cardiac arachidonic acid pools. In endothelial cells, participates in eicosanoids metabolism by converting hydroperoxide species into hydroxy epoxy metabolites. In combination with 15-lipoxygenase metabolizes arachidonic acid and converts hydroperoxyicosatetraenoates (HpETEs) into hydroxy epoxy eicosatrienoates (HEETs), which are precursors of vasodilatory trihydroxyicosatrienoic acids (THETAs). This hydroperoxide isomerase activity is NADPH- and O2-independent. Catalyzes the monooxygenation of a various xenobiotics, such as danazol, amiodarone, terfenadine, astemizole, thioridazine, tamoxifen, cyclosporin A and nabumetone. Catalyzes hydroxylation of the anthelmintics albendazole and fenbendazole. Catalyzes the sulfoxidation of fenbedazole.
基因功能參考文獻：
1. Cell survival decreases with ROS exposure when CYP2J2 is chemically inhibited. PMID: 29343610
2. Data show the importance of the formation of a hydrogen bond between cytochrome P450 2J2 arginine 117 (R117) and the keto group of the substrates. PMID: 30012976
3. these data can aid the design of other analogues that have reduced cardiotoxicity, which do not modulate CYP2J2's arachidonic acid metabolism. PMID: 29629756
4. demonstrate that doxorubicin (DOX) and 7-de-aDOX inhibit CYP2J2-mediated AA metabolism and 7-de-aDOX binds close to the active site to alter the ratio of cardioprotective epoxyeicosatrienoic acids. PMID: 29200270
5. The use of LKY-047 as a selective CYP2J2 inhibitor. PMID: 28461575
6. a computational investigation of the binding of arachidonic acid (AA) to CYP2J2 using homology modelling, induced fit docking (IFD) and molecular dynamics (MD) simulations. PMID: 27796781
7. Study found a significant interaction between CYP2J2- rs890293 and PPAR -gamma- rs1805192 and participants with GT or TT of rs890293 and CG or GG of rs1805192 genotype have the highest late-onset Alzheimer's disease risk, compared to participants with GG of rs890293 and CC of rs1805192 genotype. PMID: 27396818
8. dysregulation of the CYP epoxyeicosanoid pathway is a key pathological consequence of NASH PMID: 27401401
9. CYP2J2 is widely expressed in tissues, especially heart, vascular smooth muscle, salivary glands and placenta. Recent studies have shown that overexpression of CYP2J2 in vivo reverses several pathological processes in animals, including hypertension and other cardiovascular pathologies and insulin resistance. PMID: 27286171
10. Homocysteine (Hcy) facilitated cytochrome P-450 CYP2J2 (CYP2J2) upregulation in hepatocellular carcinoma (HCC) cells by DNA demethylation. PMID: 28030819
11. Endothelial overexpression of CYP2J2 significantly changed oxylipin profiles. PMID: 28328948
12. MAPK signaling pathway was involved in the up-regulation of CYP2J2 levels by glutamate in U251 cells. PMID: 28237619
13. -50G/T polymorphism might be a risk factor for ischemic stroke in Chinese population PMID: 28272236
14. Data show that CYP2J2 gene delivery reduced vessel wall thickening. PMID: 27459385
15. Data suggest that antiarrhythmic prodrugs amiodarone and dronedarone are extensively metabolized by CYP2J2; specific CYP2J2 metabolites include N-desbutyldronedarone and N-desethylamiodarone, potent [reversible/irreversible] inhibitors of CYP2J2. PMID: 26972388
16. Tanshinone IIA exerts its anticancer effect by inhibiting CYP2J2 activity in HepG2 cells. PMID: 26209360
17. CYP2J2 expression showed significant upregulation (P<0.05) during Cy treatment before stem cell transplantation PMID: 25601761
18. Here we present the detection of substrate binding to cytochrome P450-2J2 (CYP2J2), the predominant P450 in the human heart, using a combination of Nanodisc technology and a nanohole plasmonic sensor PMID: 26334592
19. Our results suggest that individuals with any conventional risk factor for MI along with CYP2J2*7 variant allele may be predisposed to risk of myocardial infarct in South Indian population PMID: 25560582
20. CYP2J2 and EETs prevent cardiac fibrosis and cardiac dysfunction by suppressing transmission of pro-inflammation from cardiomyocytes to macrophages in heart PMID: 25686540
21. findings can give a structural mechanism for the mutation-induced dysfunction in the CYP2J2-mediated arachidonic acid metabolism. PMID: 25204827
22. The CYP2J2 rs890293 T allele and GT+TT genotype were significantly associated with an increased risk of late onset Alzheimer disease. PMID: 25796175
23. Data suggest that up-regulation of CYP2J2 activity can attenuate type 2 diabetes and improve insulin resistance via down-regulation of NFkappaB and MAPK signaling pathways and up-regulation of PPARgamma. PMID: 25389363
24. CYP2J2 mediates bacterial phagocytosis in macrophages, and implicates a defect in the CYP2J2 pathway may regulate bacterial clearance in Crohn's disease. PMID: 24058654
25. Established and emerging roles of CYP2J2 in the biology of vascular endothelial cells. [Review] PMID: 23474289
26. CYP2J2 activity in the cell line was inhibited by danazol. PMID: 24021950
27. These findings demonstrate that Cyp2j gene products regulate the pulmonary vascular response to hypoxia PMID: 24278032
28. CYP2J2 overexpression only moderately reduced transverse aortic constriction-induced cardiac hypertrophy and did not affect the hypertrophic response to beta-adrenergic stimulation. PMID: 24023684
29. The aim of the present study was to assess the association between the human CYP2J2 gene polymorphism and coronary artery disease (CAD) in a Han and Uygur population of China. PMID: 23684773
30. Compared the effects of N-terminal modifications on the properties of CYP2J2 with respect to the activity of the protein in model lipid bilayers using Nanodiscs. PMID: 23661295
31. N404Y mutation could reposition the side-chain of Leu(378), making it no longer form a hydrogen bond with the carboxyl group of arachidonic acid. PMID: 23647230
32. Data indicate that cardiac-specific overexpression of arachidonate epoxygenase (CYP2J2) significantly protects against diabetic cardiomyopathy, which may be due to improved cardiac insulin resistance, glucose uptake, and reversal of cardiac hypertrophy. PMID: 23696562
33. High CYP2J2 expression is associated with cancer. PMID: 22761738
34. uteroplacental CYP2J2 overexpression contributes to preeclampsia. PMID: 23155181
35. This study provides evidence of potential association of CYP2J2*7 polymorphism with hypertension in the Saudi population with or without diabetes and obesity. PMID: 22731644
36. No association has been found between the CYP2J2 (rs890293, -76G > T) or CYP2S1 (rs34971233, 13106C > T, P466L and rs338583, 13255A > G) gene polymorphisms and respiratory diseases. PMID: 22232929
37. This case-control study as well as meta-analysis suggested no association between CYP2J2 G-50T and EPHX2 R287Q and the risk of developing coronary artery disease PMID: 21642892
38. CYP2J2 overexpression in cultured human-derived malignant hematologic cell lines markedly accelerated proliferation and attenuated apoptosis PMID: 21030485
39. Haplotypes of CYP2J2 are associated with myocardial infarction in a Chinese Han population. PMID: 20597138
40. Age of onset, family history, and obesity may modify typ3 2 diabetes polymorphism in younger onset typ32 diabetees. PMID: 20140850
41. The data indicate that epoxygenase 2J2 gene polymorphism is not a risk factor of acute coronary syndrome in Ukrainian population. PMID: 20480811
42. eight novel substrates for CP2J were identified that vary in size and overall topology; data suggest that CYP2J2 may be an unrecognized participant in first-pass metabolism, but its contribution is minor relative to that of CYP3A4 PMID: 19923256
43. data do not support a major role for the CYP2J2 -50G>T variant in determining blood pressure level and incident ischemic events PMID: 19851119
44. CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo PMID: 19823578
45. expression levels of the immunoreactive protein with the CYP2J2 antibody in the small intestine were well correlated with the activities of the astemizole O-demethylation PMID: 12386130
46. role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia PMID: 12737630
47. The CYP2J2*6 allele is rare in the Caucasian population, and no association is inferred between this allelic variant and type 1 or type 2 diabetic complications. PMID: 14575523
48. Transgenic mice overexpressing human CYP2J2 have improved postischemic recovery of left ventricular function. PMID: 15256482
49. Overexpressoin of CYP2J2 in transgenic mice increases l-type calcium channles in cardiomyocytes. PMID: 15361551
50. a functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary artery disease PMID: 15466638
顯示更多

收起更多
亞細胞定位：

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
蛋白家族：

Cytochrome P450 family
組織特異性：

Highly expressed in heart, present at lower levels in liver, kidney and skeletal muscle (at protein level).
數據庫鏈接：

HGNC: 2634

OMIM: 601258

KEGG: hsa:1573

STRING: 9606.ENSP00000360247

UniGene: Hs.152096

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human